On January 27, 2026, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. announced that its wholly owned subsidiary, Xiamen Innovax Biotech Co., Ltd. (“Innovax”), has maintained compliance with the World Health Organization (WHO) Prequalification (PQ) standards following a periodic re-inspection conducted by the WHO Prequalification Inspection Team (WHO PQT–INS) of its bivalent HPV vaccine, Cecolin. The vaccine was initially prequalified by WHO in 2021, and this re-inspection reaffirms its continued compliance with international quality standards.

WHO Prequalification is a globally recognized quality assurance framework that enables vaccines to be procured by United Nations agencies and supports their inclusion in national immunization programs. Sustained compliance with WHO PQ standards reflects the ability to consistently meet international benchmarks for quality, safety, and manufacturing, and plays an important role in advancing access to vaccines worldwide.

Leveraging a robust quality system and scalable manufacturing capabilities, Innovax’s bivalent HPV vaccine, Cecolin, has been approved in 25 countries and introduced into national immunization programs in more than 10 countries. As of 2025, about 80 million doses have been supplied globally, contributing to improved access to HPV vaccines.

Global progress in HPV vaccination has been recognized by The Guardian as one of the major global health achievements of 2025, with Innovax’s continued and reliable supply contributing to improved vaccine access.

As the first HPV vaccine developed in Asia, Cecolin has been used across multiple markets, supporting cervical cancer prevention efforts. In addition, Innovax’s 9-valent HPV vaccine, Cecolin 9, was approved by China’s National Medical Products Administration (NMPA) in May 2025. The introduction of Cecolin 9 provides an additional option to support multi-tier immunization strategies and broader population coverage.

Sustained WHO PQ compliance reflects Innovax’s consistent performance in quality management, manufacturing reliability, and supply capability, supporting continued use across global public health systems.

Looking ahead, Innovax will continue to advance innovation-driven development and strengthen its global quality system, with a focus on improving vaccine accessibility and affordability, and supporting global efforts to eliminate cervical cancer and advance broader public health outcomes.